Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5112828 | 0.91 | ALDH1A1 (0.48) | CNR1CYP2C19ALDH1A1KDM4EUSP2 | |
| SCHEMBL5106083 | 0.82 | CNR1 (0.54) | CNR1 | |
| SCHEMBL5110891 | 0.79 | CNR1 (0.57) | CNR1 | |
| SCHEMBL5103007 | 0.78 | CNR1 (0.60) | CNR1ALDH1A1TP53 | |
| SCHEMBL5111599 | 0.77 | CNR1 (0.54) | CNR1 | |
| SCHEMBL5795128 | 0.77 | CNR1 (0.64) | CNR1 | |
| SCHEMBL5113110 | 0.77 | CNR1 (0.51) | CNR1ALDH1A1 | |
| SCHEMBL5106047 | 0.76 | CNR1 (0.57) | CNR1ALDH1A1GLA | |
| SCHEMBL1260541 | 0.76 | CNR1 (0.60) | CNR1CYP2C19ALDH1A1KDM4EUSP2 | |
| SCHEMBL2327666 | 0.76 | CNR1 (0.48) | CNR1CYP2C19ALDH1A1KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | claimed |
| US-7320978-B2 | Oxazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2008-01-22 | — | — | US | disclosed |
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | OXA1L, ARG2, CYP3A7 | CNR1 246/4885CYP2C19 16/4885ALDH1A1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.